Dr. Lunning on Trials Evaluating BTK Inhibitors in CLL

Video

Matthew A. Lunning, DO, FACP, discusses trials evaluating BTK inhibitors in chronic lymphocytic leukemia.

Matthew A. Lunning, DO, FACP, assistant vice chair of research, the Department of Medicine, assistant vice chancellor of Clinical Research, associate professor of Internal Medicine, the Division of Hematology and Oncology, the University of Nebraska Medical Center, discusses trials evaluating BTK inhibitors in chronic lymphocytic leukemia (CLL).

Ibrutinib (Imbruvica)-based combinations have driven much of the data for clinical trials in CLL, such as the phase 2 CAPTIVATE trial (NCT02910583) with fixed-duration therapy in treatment-naïve patients with CLL, Lunning notes. In CAPTIVATE, patients in the fixed-duration cohort received an ibrutinib lead-in for 3 cycles, followed by 12 cycles of venetoclax (Venclexta) plus ibrutinib, Lunning says. CAPTIVATE marked one of the first trial exploring minimal residual disease [MRD] approaches in terms of determining which patients had undetectable MRD and what the threshold was for undetectable MRD, Lunning explains. The trial also aimed to prevent hospitalizations by ramping up dosing of venetoclax, Lunning adds. 

Since CAPTIVATE explored a time-limited therapy, rather than continuous therapy, it opened the possibility for these agents to remain as treatment options in later lines for these patients, Lunning continues. The CAPTIVATE trial also looked at outcomes for patients with deletion 17P and TP53 mutations to determine if fixed-duration therapy could elicit favorable outcomes in these high-risk patients, Lunning concludes.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD